Literature DB >> 9233486

Results of speech processor upgrade in a population of Veterans Affairs cochlear implant recipients.

N L Cohen1, S B Waltzman, J T Roland, B Bromberg, N Cambron, L Gibbs, W Parkinson, C Snead.   

Abstract

OBJECTIVE: This study aimed to evaluate the change in performance when the Speak processing strategy replaced the Mpeak strategy.
SUBJECTS: Twenty-one veterans who participated in the original Department of Veterans Affairs Multicenter Cochlear Implant Study, received the Nucleus F0F1F2 processor (Cochlear Corp., Englewood, CO, U.S.A.) (WSP) and were subsequently upgraded to the Mpeak (MSP) processing strategy.
METHODS: Closed- and open-set speech recognition in quiet and in noise in auditory only conditions at the phoneme, word, and sentence levels were evaluated.
RESULTS: Changes in audiologic parameters were evaluated using a paired t-test for related samples. Statistically significant improvements in mean scores were found for all tests and were greatest for the speech-in-noise conditions. An examination of individual data revealed that 61% of the subjects improved for tests administered in quiet, whereas up to 69% of the subjects had improved performance in noise. Subjects with no open set speech discrimination using the Mpeak strategy showed no improvement with the Speak strategy.
CONCLUSIONS: Cochlear implants can provide improved performance using modifications to external speech processor hardware and software without changing the internal implant.

Mesh:

Year:  1997        PMID: 9233486

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  2 in total

1.  Hearing restoration: Graeme Clark, Ingeborg Hochmair, and Blake Wilson receive the 2013 Lasker~DeBakey Clinical Medical Research Award.

Authors:  Corinne Williams
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

2.  [Influence of "novel" speech processors on the speech perception performance of cochlear implant users].

Authors:  I Baljić
Journal:  HNO       Date:  2009-06       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.